Cargando…

Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak

Background: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Francesca, Ricci, Rosalba, Belmonti, Simone, Fabbiani, Massimiliano, Borghetti, Alberto, Baldin, Gianmaria, Ciccullo, Arturo, Tamburrini, Enrica, Visconti, Elena, Sanguinetti, Maurizio, Di Giambenedetto, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303907/
https://www.ncbi.nlm.nih.gov/pubmed/34202510
http://dx.doi.org/10.3390/diagnostics11071154
_version_ 1783727202839298048
author Lombardi, Francesca
Ricci, Rosalba
Belmonti, Simone
Fabbiani, Massimiliano
Borghetti, Alberto
Baldin, Gianmaria
Ciccullo, Arturo
Tamburrini, Enrica
Visconti, Elena
Sanguinetti, Maurizio
Di Giambenedetto, Simona
author_facet Lombardi, Francesca
Ricci, Rosalba
Belmonti, Simone
Fabbiani, Massimiliano
Borghetti, Alberto
Baldin, Gianmaria
Ciccullo, Arturo
Tamburrini, Enrica
Visconti, Elena
Sanguinetti, Maurizio
Di Giambenedetto, Simona
author_sort Lombardi, Francesca
collection PubMed
description Background: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test; Results: overall, 1389 samples were analyzed from 1106 PLWH: 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March–June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37–1.42). Conclusion: our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population.
format Online
Article
Text
id pubmed-8303907
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83039072021-07-25 Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak Lombardi, Francesca Ricci, Rosalba Belmonti, Simone Fabbiani, Massimiliano Borghetti, Alberto Baldin, Gianmaria Ciccullo, Arturo Tamburrini, Enrica Visconti, Elena Sanguinetti, Maurizio Di Giambenedetto, Simona Diagnostics (Basel) Article Background: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test; Results: overall, 1389 samples were analyzed from 1106 PLWH: 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March–June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37–1.42). Conclusion: our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population. MDPI 2021-06-24 /pmc/articles/PMC8303907/ /pubmed/34202510 http://dx.doi.org/10.3390/diagnostics11071154 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lombardi, Francesca
Ricci, Rosalba
Belmonti, Simone
Fabbiani, Massimiliano
Borghetti, Alberto
Baldin, Gianmaria
Ciccullo, Arturo
Tamburrini, Enrica
Visconti, Elena
Sanguinetti, Maurizio
Di Giambenedetto, Simona
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
title Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
title_full Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
title_fullStr Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
title_full_unstemmed Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
title_short Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
title_sort seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303907/
https://www.ncbi.nlm.nih.gov/pubmed/34202510
http://dx.doi.org/10.3390/diagnostics11071154
work_keys_str_mv AT lombardifrancesca seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT riccirosalba seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT belmontisimone seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT fabbianimassimiliano seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT borghettialberto seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT baldingianmaria seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT cicculloarturo seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT tamburrinienrica seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT viscontielena seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT sanguinettimaurizio seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak
AT digiambenedettosimona seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak